/
Respiratory
Asthma
132
Pipeline Programs↗
255
Active Trials↗
136
Companies Involved↗
Asthma is a highly competitive landscape with 132 programs across 136 companies. The most active players are GSK, Guangdong Hengrui Pharmaceutical Co., Ltd, Novartis. 20 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical79
Phase 15
Phase 228
Approved
No programs
Analysis
Modality Breakdown
96%
Small molecule
103 of 107 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 107 classified programs, each share of the total. Modality classified for 94% of 132 pipeline programs.
Analysis
Trial Status
1,790
clinical trials
Completed1,223 · 68%
Recruiting146 · 8%
Terminated130 · 7%
Unknown status114 · 6%
Withdrawn65 · 4%
Active, not recruiting56 · 3%
Other56 · 3%
Clinical Trials
Trial Activity
1790 trials
Page 1 of 120
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)